Associations of meningioma molecular subgroup and tumor recurrence.

Youngblood M. W., Miyagishima D. F., Jin L., Gupte T., Li C., Duran D., ...Daha Fazla

Neuro-oncology, cilt.23, sa.5, ss.783-794, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1093/neuonc/noaa226
  • Dergi Adı: Neuro-oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.783-794
  • Anahtar Kelimeler: meningioma genomics, molecular subgroups, precision medicine, tumor prognosis, TERT PROMOTER MUTATIONS, ALLELIC LOSS, AKT1, SMO, CLASSIFICATION, PROGRESSION, SYSTEM
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background. We and others have identified mutually exclusive molecular subgroups of meningiomas; however, the implications of this classification for clinical prognostication remain unclear. Integrated genomic and epigenomic analyses implicate unique oncogenic processes associated with each subgroup, suggesting the potential for divergent clinical courses. The aim of this study was to understand the associated clinical outcomes of each subgroup, as this could optimize treatment for patients.